← Leaderboards
Jing Zeng
University Of Washington
$2,332,875
Attributed
$4,665,750
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $622.3K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,665,750 · 2
By mechanism
R01$4,665,750 · 2
Top collaborators
- Stephen R. Bowen9 shared
Most similar at University Of Washington
Same institution · by research overlap
- Donna L. Berry$7,674,074
- Satoshi Minoshima$4,227,996
- Stephen R. Bowen$2,332,875
- Kenneth A. Krohn$5,749,811
- Adam M Alessio$3,764,521
Others in their field
Top investigators on “Non-Small-Cell Lung Carcinoma”
- Walter John Curran · Thomas Jefferson University$26,641,549
- Pasi A Janne · Stanford University$23,565,845
- Kwok Kin Wong · New York University School Of Medicine$17,033,021
- Trever G Bivona · University Of California, San Francisco$12,986,639
- Reuben J Shaw · Salk Institute For Biological Studies$11,952,012
- Matthew L Meyerson · Brigham And Women'S Hospital$11,175,304
Research focus
Non-Small-Cell Lung CarcinomaQuantitative ImagingPositron-Emission TomographyPatient-Focused OutcomesTumorResponseMalignant Neoplasm Of LungRandomized TrialRadiation TherapyRadiationToxic EffectCancer ControlUptakeX-Ray Computed TomographyHigh RiskFluorodeoxyglucose Positron Emission TomographyImproved OutcomeChemotherapyPatient StratificationImageBaseCancer SurvivalCancer PatientAttenuation
Grant awards (9)
Biomarkers of Response to Immuno-chemotherapy & oliGometastatic Hypofractionated radioTherapy (BRIGHT) for Lung Cancer: Synergy of PET/CT Imaging and Peripheral Blood Assays$608,411
R01 · FY2025 · CA
Biomarkers of Response to Immuno-chemotherapy & oliGometastatic Hypofractionated radioTherapy (BRIGHT) for Lung Cancer: Synergy of PET/CT Imaging and Peripheral Blood Assays$577,989
R01 · FY2024 · CA
Biomarkers of Response to Immuno-chemotherapy & oliGometastatic Hypofractionated radioTherapy (BRIGHT) for Lung Cancer: Synergy of PET/CT Imaging and Peripheral Blood Assays$596,244
R01 · FY2023 · CA
Biomarkers of Response to Immuno-chemotherapy & oliGometastatic Hypofractionated radioTherapy (BRIGHT) for Lung Cancer: Synergy of PET/CT Imaging and Peripheral Blood Assays$622,286
R01 · FY2022 · CA
Personalized radiation therapy through functional lung avoidance and response-adaptive dose escalation: utilizing multimodal molecular imaging to improve the therapeutic ratio$437,492
R01 · FY2020 · CA
Personalized radiation therapy through functional lung avoidance and response-adaptive dose escalation: utilizing multimodal molecular imaging to improve the therapeutic ratio$447,526
R01 · FY2019 · CA
Personalized radiation therapy through functional lung avoidance and response-adaptive dose escalation: utilizing multimodal molecular imaging to improve the therapeutic ratio$461,368
R01 · FY2018 · CA
Personalized radiation therapy through functional lung avoidance and response-adaptive dose escalation: utilizing multimodal molecular imaging to improve the therapeutic ratio$461,368
R01 · FY2017 · CA
Personalized radiation therapy through functional lung avoidance and response-adaptive dose escalation: utilizing multimodal molecular imaging to improve the therapeutic ratio$453,066
R01 · FY2016 · CA